DELRAY BEACH, Fla., May 12, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (Nasdaq:PSID), a leader in next generation patient monitoring and diagnostics, will host a conference call and webcast for investors, media and other interested parties on Monday, May 16, 2011 at 10:00 am ET, to discuss its acquisition of MicroFluidic Systems ("MFSI"). Founded in 2001, MFSI specializes in the production of automated instruments for a wide range of applications in the detection and processing of biological samples. MFSI's strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products.
Conference Call and Webcast Information
To participate in the live call, please dial (888) 419-5570 within the U.S. or (617) 896-9871 internationally, and use passcode 50837076. Alternatively, a simultaneous webcast of the live conference call can be accessed through PositiveID's website at www.positiveidcorp.com in the Investors & Media section under Events & Presentations. For those unable to participate in the conference call or the webcast, a replay will be available from May 16, 2011 at approximately 8:00 pm ET to May 23, 2011 at 11.59 pm ET. For the replay, dial (888) 286-8010 (USA) or (617) 801-6888 (international), and use access code 83885124. Alternatively, a replay can be accessed on PositiveID's website at www.positiveidcorp.com through the Investor Relations section under Events & Presentations.
About MicroFluidic Systems
MicroFluidic Systems (MFSI), www.microfluidicsystems.com, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. MFSI personnel have been involved with the development of automated DNA-based pathogen detection systems and microfluidics for the U.S. Government and commercial markets for over 25 years, including the world's first miniaturized, portable, battery-operated, real-time, PCR-based detection system.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's and MFSI's future expectations, including the likelihood that MFSI's strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to complete its acquisition of MFSI, the likelihood that MFSI's strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Allison Tomek 561-805-8000 email@example.com Dan Schustack CEOcast 212-732-4300 firstname.lastname@example.org